L’E-learning et les nouvelles technologies de l'image dans les travaux pratiques d‘Histologie en Médecine vétérinaire : Impacts sur la motivation et la maîtrise de l'apprentissage.

Additional file 8: Table S2. Free prostate specific antigen (fPSA), total PSA (tPSA), free to total PSA (f/tPSA) and prostate cancer antigen3 (PCA3) median and IQR values for the four classifications utilized in the PCa study

MOESM7 of MALDI-TOF peptidomic analysis of serum and post-prostatic massage urine specimens to identify prostate cancer biomarkers

Additional file 7: Figure S3. Scatterplots of the within-subject replicates vs mean values and a QQ plot of the differences of between-subjects replicates, Serum

Genetics in TNF-TNFR pathway: A complex network causing spondyloarthritis and conditioning response to anti-TNFα therapy

<div><p>Objectives</p><p>We investigated whether polymorphisms (SNPs) in the promoter region of <i>TNFA</i>, or in the autoinflammatory <i>TNFRSF1A</i> and <i>MEFV</i> genes, concur with <i>HLA-B27</i> in enhancing the risk of Spondyloarthritis (SpA) and/or in predicting the response to anti-TNFα treatment.</p><p>Methods</p><p>373 controls and 137 SpA (82 with Psoriatic Arthritis-PsA and 55 with Ankylosing Spondylitis- AS; 98/137 under TNFα inhibitor therapy) from the Veneto Region (Italy) were studied. <i>TNFA</i> polymorphisms (-1031T>C;-857C>T;-376G>A;-308G>A;-238G>A) and <i>HLA-B27</i> were assayed by RT-PCR. Direct sequencing of <i>MEFV</i> (exons 2,3,5 and 10) and <i>TNFRSF1A</i> (exons 2,3,4 and 6) genes were performed.</p><p>Results</p><p><i>HLA-B27</i> was associated with AS (χ² = 120.1; p = 0.000). Only the <i>TNFA</i> -1031T>C was singly associated with SpA, and the haplotype C/G, resulting from -1031T>C/-308G>A combination, was significantly associated with a reduced risk of SpA (OR: 0.67, CI: 0.46–0.97; p = 0.035). Two SNPs were identified in <i>TNFRSF1A</i>, the R92Q (Minor allele frequency-MAF = 0.034) and c.625+10A>G (MAF = 0.479). None of them was associated with SpA (p>0.05). The <i>TNFRSF1A</i> c.625+10 G allele was associated with late response to anti-TNFα therapy (p = 0.031). Twenty-one SNPs were identified in <i>MEFV</i> gene, 10 with a known potential functional significance. Variant alleles were extremely rare in our population (MAF<0.025) except for R202Q (MAF = 0.27). None was associated with SpA diagnosis (p>0.05).</p><p>Conclusion</p><p><i>TNFRSF1A</i> and <i>MEFV</i> gene SNPs are not associated with SpA in the North-East of Italy. AS risk appears to depend not only on <i>HLA-B27</i>, but also on the protective <i>TNFA</i> haplotype -1031C/-308G. The <i>TNFRSF1A</i> c.625+10A>G impacts on the response to anti-TNFα therapy.</p></div

MOESM11 of MALDI-TOF peptidomic analysis of serum and post-prostatic massage urine specimens to identify prostate cancer biomarkers

Additional file 11: Raw data 2. Raw data for estimating signal sLOD

<i>TNFA</i> gene polymorphisms in controls, AS and PsA patients.

<p><i>TNFA</i> gene polymorphisms in controls, AS and PsA patients.</p

Haematological and biochemical data in controls, AS and PsA patients at enrolment.

<p>Haematological and biochemical data in controls, AS and PsA patients at enrolment.</p

Logistic regression analyses considering SpA diagnosis as the outcome variable and <i>TNFA</i> haplotype combinations as predictors.

<p>Logistic regression analyses considering SpA diagnosis as the outcome variable and <i>TNFA</i> haplotype combinations as predictors.</p

<i>HLA</i> alleles, <i>TNFA</i> and <i>TNFRSF1A</i> genetics and response to TNF-α inhibitors.

<p><i>HLA</i> alleles, <i>TNFA</i> and <i>TNFRSF1A</i> genetics and response to TNF-α inhibitors.</p

MOESM5 of MALDI-TOF peptidomic analysis of serum and post-prostatic massage urine specimens to identify prostate cancer biomarkers

Additional file 5: Results. Monte Carlo simulations results confirmed that substituting the limit of detection (LOD) with LOD/2 does not affect the reliability of ICC estimation; The measurement error structure of peptidomi MALDI-TOF/MS-based analysis of the urinary and serum feature

Demographic, clinical characteristics, laboratory indices and outcome measures.

<p><b>The demographic characteristics were those obtained at enrolment, while patients’ clinical data and laboratory indices are referred to findings obtained at diagnosis of AS or PsA disease</b>.</p